Celltrion to Secure 570,000-Liter Global Production Capacity... Enhancing Capabilities Through Automation
Strengthening Cost Competitiveness, Supply Stability, and CDMO Foundations
Proactively Responding to Global Pharmaceutical Demand
Celltrion is enhancing its production capabilities by expanding its facilities and adopting advanced technologies. These efforts are intended to proactively address the growing global market share of its main products, the development of its pipeline, and orders for contract development and manufacturing organization (CDMO) services. In addition, as global demand for biopharmaceuticals continues to rise, the company expects to achieve results such as strengthened cost competitiveness, greater supply stability, and the establishment of a solid CDMO business foundation by building a sustainable production infrastructure. Celltrion aims to maximize its dominance in the global market based on both domestic and overseas production bases and to establish itself as a leading global big pharma company.
Celltrion Secures 570,000-Liter Capacity Domestically and Abroad... Securities Industry: "Preemptive Expansion Ensures Competitiveness"
According to the pharmaceutical and biotech industry on June 24, Celltrion currently operates production infrastructure at its first to third plants in Songdo, Incheon, with a combined capacity of approximately 250,000 liters. Since becoming the first company in Asia to receive U.S. FDA approval for current Good Manufacturing Practice (cGMP) standards in 2007, Celltrion has obtained certifications from advanced regulatory agencies such as the FDA and the European Medicines Agency (EMA) for all its production facilities, and continues to produce high-quality biopharmaceuticals for export.
Furthermore, Celltrion is making bold investments in facility expansion and plans to incrementally expand its infrastructure at domestic and U.S. production sites from this year through 2030. In Korea, the company will invest KRW 1.2265 trillion to simultaneously construct its fourth and fifth drug substance (DS) plants, adding a total capacity of 180,000 liters. With the addition of these new plants to the existing 250,000-liter infrastructure of the first to third plants, Celltrion will have a total domestic DS production capacity of 430,000 liters.
At the same time, Celltrion has decided to expand the Branchburg plant in New Jersey, which it acquired from Eli Lilly in the U.S. last year and which has a capacity of 66,000 liters, by an additional 75,000 liters. This will give Celltrion a total DS production capacity of 141,000 liters in the United States. Through these expansions, Celltrion will ultimately secure a global DS production capacity of 571,000 liters. Once this level of production capability is established, Celltrion’s DS production capacity will rank among the top five globally, even when compared to major global CDMO firms and big pharma companies.
This expansion strategy represents Celltrion’s commitment to a “global two-track” strategy in production base operations. By diversifying its production bases, the company aims to mitigate geopolitical uncertainties and strengthen cost competitiveness through large-scale in-house production.
Separately, Celltrion is also expanding its drug product (DP) production capacity. The new DP plant being built in Songdo, Incheon, will have twice the annual maximum output of the DP production line at the existing second plant, producing approximately 8 million vials (small glass bottles for medicines). Upon completion, Celltrion will have the capacity to manufacture a total of 12 million DP vials. The company is also pursuing the construction of a new DP plant in Yesan, South Chungcheong Province.
Based on its enhanced production infrastructure and extensive experience accumulated throughout the entire biopharmaceutical business cycle, Celltrion is expanding its contract manufacturing organization (CMO) and CDMO businesses. Recently, the company has diversified its business portfolio by signing CMO contracts with multiple global pharmaceutical companies, thereby extending its production capabilities to external clients.
Isu Jung, a researcher at IBK Investment & Securities, stated, "With blockbuster pharmaceuticals facing patent expirations, market opportunities are structurally likely to expand, and Celltrion's target market for biosimilars in 2038 is projected to reach KRW 408 trillion—more than four times the current market size." Jung added, "As supply stability is the key to securing biosimilar market share during this period of market expansion, preemptive production capacity expansion is highly significant in terms of competitiveness." According to Fortune Business Insights, the global CDMO market is expected to grow at a compound annual growth rate of 9.9%, expanding from USD 273.4 billion (approximately KRW 419.2589 trillion) this year to USD 580.7 billion (approximately KRW 890.5034 trillion) by 2034.
Introducing Physical AI in New Plants... Maximizing Efficiency Through Smart Factories
Celltrion is establishing a smart factory based on "Physical AI" at its new fourth and fifth plants, aiming to maximize efficiency and flexibility in its production processes. This approach will enable the company to respond quickly not only to current flagship products but also to next-generation biosimilars and new drug pipelines scheduled for release in the future.
The new fourth and fifth plants will be equipped with autonomous mobile robots (AMR), automated logistics warehouses, intelligent robotic arms, advanced collaborative robots, and manufacturing management software, increasing the level of factory automation. Until the plants are completed, the company will prioritize automating standardized tasks. Subsequently, it plans to integrate AI into high-value judgment work to maximize production efficiency. In the long term, depending on the maturity of relevant technologies, Celltrion plans to deploy humanoid robots to achieve unmanned operation even for complex, non-standardized tasks at a human level.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative commented, "The strategy of simultaneously building large-scale production infrastructure and innovating manufacturing through AI will be a key factor in strengthening Celltrion's mid- to long-term competitiveness. Stable production capabilities and a secure supply chain provide a critical foundation for expanding market dominance, and this enhancement of production capacity will accelerate our progress toward becoming a global big pharma company."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.